Based on competence and long-standing experience, Red Glead Discovery offers first-rate research services for drug discovery. In-house laboratory capabilities comprise medicinal chemistry, biology, analytical chemistry and ADME. An expert area is generation of chemical starting points for drug targets and to develop them into patentable lead compounds with drug-like properties and low risk profile. Our project management skills and cross-disciplinary capabilities make us a preferred partner for clients that want to develop compounds with high potential to become successful drugs.
inSili.com offers an elite source of intellectual property and unique expertise for innovative pharmaceutical and biotechnological research and development. The company provides know-how and world-leading technology for virtual screening of pioneering de novo designed molecular agents.
inSili.com's founders created and defined the terms "scaffold-hopping" and "frequent-hitters" in drug discovery. The company’s industry-proven molecular design concept is built on groundbreaking algorithms like CATS (Chemically Advanced Template Search) and DOGS (Design Of Genuine Structures) and a unique Collection Of Bioactive Reference Analogs (COBRA) for the discovery of new chemical entities featuring desired properties and tailored polypharmacology. inSili.com's unrivaled target prediction technique enables the "deorphaning" of bioactive agents like natural products and phenotypic screening hits. Own technology development and drug discovery projects continuously strengthen inSili.com's innovation potential.
CARNA BIOSCIENCES, Inc is a biopharmaceutical company focused on the discovery and development of proprietary kinase inhibitor drugs to treat serious unmet medical needs. By leveraging expertise and experiences accumulated through its own drug discovery efforts, Carna has established extensive distribution channels as a reliable service provider, and has proven to be an excellent supplier of high-quality drug discovery support services to scientists worldwide. Carna Biosciences was founded in Kobe, Japan, in 2003 as a spinoff of Japan Organon (Nippon Organon KK). Carna is a publicly traded company in the JASDAQ of the Tokyo Stock Exchange with securities code, 4572.
Among the drug discovery supporting products and services Carna Biosciences provides:
1. Kinase Protein
2. Profiling Services
3. Assay Development
5. Cell Based Assay Services